IMMOFINANZ AG

  • WKN: A2JN9W
  • ISIN: AT0000A21KS2
  • Land: Österreich

Nachricht vom 06.10.2021 | 11:54

IMMOFINANZ AG: Other admission duties to follow

IMMOFINANZ AG / Notice pursuant to section 120 para 2 no 1 of the Austrian Stock Exchange Act 2018
06.10.2021 / 11:54
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notice pursuant to section 120 para 2 no 1 of the Austrian Stock Exchange Act 2018

IMMOFINANZ AG: Change in number of exercisable voting rights


ISIN: AT0000A21KS2

Pursuant to section 120 para 2 no 1 of the Austrian Stock Exchange Act 2018, IMMOFINANZ AG hereby notifies that at the time of this publication the number of exercisable voting rights amounts to a total of 123,292,767 voting rights.

The change in the number of exercisable voting rights results from the issuance of 6,997,200 treasury shares to the holders of the mandatory convertible notes due 2023 due to an early mandatory conversion by IMMOFINANZ AG.

The share capital remains unchanged at EUR 123,293,795.00 and is divided into 123,293,795 ordinary no-par value shares representing a portion of the share capital of IMMOFINANZ AG of EUR 1.00 each.

For additional information contact:
Bettina Schragl
Head of Corporate Communications and Investor Relations
T +43 (0)1 88 090 2290
M +43 (0)699 1685 7290
communications@immofinanz.com
investor@immofinanz.com



06.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021